Global Health Limited, operating as Medanta, is a premier for-profit private hospital network based in Gurgaon, India. Founded in 2009 by the esteemed cardiac surgeon Dr. Naresh Trehan and entrepreneur Sunil Sachdeva, Medanta has emerged as a leading healthcare institution nationwide. Renowned for its cutting-edge medical infrastructure, innovative technology, and a team of highly skilled medical professionals, Medanta provides an extensive array of specialized medical services, encompassing cardiology, neurology, oncology, orthopedics, and organ transplantation, among others. Committed to delivering excellence in healthcare with a patient-centric approach, Medanta continuously raises the bar for quality standards within the Indian healthcare sector.
History of Global Health Ltd (MEDANTA)
Medanta’s inception dates back to 2004 when renowned cardiac surgeon Naresh Trehan, alongside Sunil Sachdeva, embarked on the venture following Trehan’s departure from Escorts Heart Institute. Subsequently, in 2006, Avenue Capital Group injected ₹224 crore (US$49.44 million) into the project. The flagship hospital, Medanta – The Medicity, was established in Gurgaon in 2009, boasting 1250 beds and cutting-edge facilities, with an estimated investment of ₹1,200 crore (US$247.91 million). In 2013, Carlyle Group acquired a 27% stake from Avenue Capital Group for ₹960 crore (US$163.83 million), valuing Medanta at ₹3,550 crore (US$605.82 million). Over time, Singapore-based Temasek Holdings acquired a 17.74% stake from Punj Lloyd. Medanta’s expansion included the launch of a 160-bed hospital in Indore and the acquisition of the Abdur Razzaque Ansari Memorial Weavers’ Hospital in Ranchi. In 2018, it opened a 200-bed facility in Sri Ganganagar, followed by the inauguration of a 1000-bed multi-specialty hospital in Lucknow in 2019, constructed at a cost of ₹1,000 crore (US$155.88 million). Despite Manipal Hospitals’ proposed acquisition of Medanta for ₹5,800 crore (US$823.63 million) in 2019, the deal fell through. In 2021, Medanta further expanded with the inauguration of the 500-bed Jay Prabha Medanta Super Specialty Hospital in Patna, culminating in its initial public offering (IPO) in November 2022.
Medanta Q4 FY24 Results: Summary and Key Points
- Net profit for Q4 FY24 increased by 25% year-on-year, reaching ₹127.3 crore compared to ₹101.8 crore in the same quarter last year.
- Revenue from operations grew by 14% year-on-year, totaling ₹808 crore for the quarter, up from ₹707 crore in the year-ago period.
- Established in 2004 by Dr. Naresh Trehan, Global Health Ltd operates Medanta Medicity, a super-specialty tertiary-care hospital in Gurugram.
- Medanta Medicity, with a capacity of 1,400 beds, commenced operations in November 2009.
- In FY15, Medanta expanded its operations by entering into an arrangement to manage 150-bed hospitals in Indore and Ranchi.
- Medanta also operates hospitals in Lucknow and Patna.
- Additionally, a new hospital is in the process of being set up in Noida, Uttar Pradesh.
How to Purchase Global Health Ltd Shares in India?
Below are the trading platforms that you can use to purchase Global Health Ltd shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
Global Health Ltd Share Price Prediction: 2024, 2025 to 2030
Global Health Ltd Share Price Target 2024
| When | Maximum Price | Minimum Price |
| May 2024 | 1,354.80 | 1,178.09 |
| June 2024 | 1,403.58 | 1,220.50 |
| July 2024 | 1,389.54 | 1,208.30 |
| August 2024 | 1,445.12 | 1,256.63 |
| September 2024 | 1,502.93 | 1,306.89 |
| October 2024 | 1,473.46 | 1,281.27 |
| November 2024 | 1,532.40 | 1,332.52 |
| December 2024 | 1,547.72 | 1,345.84 |
In May 2024, Medanta’s shares are projected to reach a maximum price of 1,354.80 and a minimum price of 1,178.09. As we move into June 2024, the maximum price is expected to increase to 1,403.58, with a minimum price of 1,220.50. July 2024 sees the maximum price at 1,389.54 and the minimum at 1,208.30. August 2024 forecasts a maximum price of 1,445.12 and a minimum of 1,256.63. September 2024 anticipates a maximum price of 1,502.93 and a minimum of 1,306.89. October 2024’s projection is a maximum price of 1,473.46 and a minimum of 1,281.27. November 2024 foresees the maximum price rising to 1,532.40, with a minimum of 1,332.52. Finally, December 2024 is expected to have a maximum price of 1,547.72 and a minimum of 1,345.84 for Medanta’s shares.
Global Health Ltd Share Price Target 2025
| When | Maximum Price | Minimum Price |
| January 2025 | 1,563.20 | 1,202.46 |
| February 2025 | 1,578.99 | 1,214.61 |
| March 2025 | 1,612.15 | 1,240.11 |
| April 2025 | 1,596.18 | 1,227.83 |
| May 2025 | 1,549.69 | 1,192.07 |
| June 2025 | 1,619.43 | 1,245.72 |
| July 2025 | 1,587.68 | 1,221.29 |
| August 2025 | 1,636.78 | 1,259.06 |
| September 2025 | 1,656.42 | 1,274.17 |
| October 2025 | 1,699.49 | 1,307.30 |
| November 2025 | 1,741.98 | 1,339.98 |
| December 2025 | 1,820.36 | 1,400.28 |
As we progress through 2025, Medanta’s shares are anticipated to fluctuate monthly. In January, the stock is projected to reach a maximum price of 1,563.20 and a minimum of 1,202.46. By December, the trajectory suggests a potential rise, with the maximum price estimated at 1,820.36 and the minimum at 1,400.28.
Global Health Ltd Share Price Prediction 2026
| When | Maximum Price | Minimum Price |
| January 2026 | 1,874.98 | 1,442.29 |
| February 2026 | 1,828.10 | 1,406.23 |
| March 2026 | 1,864.66 | 1,434.36 |
| April 2026 | 1,902.72 | 1,463.63 |
| May 2026 | 1,883.88 | 1,449.14 |
| June 2026 | 1,930.98 | 1,485.37 |
| July 2026 | 1,893.11 | 1,456.24 |
| August 2026 | 1,951.66 | 1,501.28 |
| September 2026 | 1,990.70 | 1,531.31 |
| October 2026 | 2,042.45 | 1,571.12 |
| November 2026 | 2,093.52 | 1,610.40 |
| December 2026 | 2,145.85 | 1,650.66 |
Global Health Ltd Share Price Prediction 2027
| When | Maximum Price | Minimum Price |
| January 2027 | 2,167.31 | 1,667.16 |
| February 2027 | 2,222.88 | 1,709.91 |
| March 2027 | 2,309.58 | 1,776.60 |
| April 2027 | 2,264.29 | 1,741.76 |
| May 2027 | 2,198.34 | 1,691.03 |
| June 2027 | 2,297.27 | 1,767.13 |
| July 2027 | 2,252.22 | 1,732.48 |
| August 2027 | 2,321.88 | 1,786.06 |
| September 2027 | 2,403.14 | 1,848.57 |
| October 2027 | 2,465.63 | 1,896.64 |
| November 2027 | 2,527.27 | 1,944.05 |
| December 2027 | 2,590.45 | 1,992.65 |
Global Health Ltd Share Price Target 2028
| When | Maximum Price | Minimum Price |
| January 2028 | 2,642.26 | 2,032.51 |
| February 2028 | 2,710.01 | 2,084.62 |
| March 2028 | 2,815.70 | 2,165.92 |
| April 2028 | 2,760.49 | 2,123.45 |
| May 2028 | 2,680.09 | 2,061.60 |
| June 2028 | 2,800.69 | 2,154.38 |
| July 2028 | 2,745.77 | 2,112.13 |
| August 2028 | 2,830.69 | 2,177.46 |
| September 2028 | 2,929.77 | 2,253.67 |
| October 2028 | 3,005.94 | 2,312.26 |
| November 2028 | 3,081.09 | 2,370.07 |
| December 2028 | 3,158.12 | 2,429.32 |
Global Health Ltd Share Price Target 2029
| When | Maximum Price | Minimum Price |
| January 2029 | 3,221.28 | 2,477.91 |
| February 2029 | 3,303.88 | 2,541.44 |
| March 2029 | 3,432.73 | 2,640.56 |
| April 2029 | 3,365.42 | 2,588.79 |
| May 2029 | 3,267.40 | 2,513.38 |
| June 2029 | 3,414.43 | 2,626.49 |
| July 2029 | 3,347.48 | 2,574.99 |
| August 2029 | 3,451.01 | 2,654.62 |
| September 2029 | 3,571.80 | 2,747.54 |
| October 2029 | 3,664.66 | 2,818.97 |
| November 2029 | 3,756.28 | 2,889.45 |
| December 2029 | 3,850.19 | 2,961.68 |
Global Health Ltd Share Price Target 2030
| When | Maximum Price | Minimum Price |
| January 2030 | 3,927.19 | 3,020.92 |
| February 2030 | 4,027.89 | 3,098.38 |
| March 2030 | 4,184.98 | 3,219.21 |
| April 2030 | 4,102.92 | 3,156.09 |
| May 2030 | 3,983.42 | 3,064.17 |
| June 2030 | 4,162.67 | 3,202.05 |
| July 2030 | 4,081.05 | 3,139.27 |
| August 2030 | 4,207.27 | 3,236.36 |
| September 2030 | 4,354.52 | 3,349.63 |
| October 2030 | 4,467.74 | 3,436.72 |
| November 2030 | 4,579.43 | 3,522.64 |
| December 2030 | 4,693.92 | 3,610.71 |
In 2030, Medanta’s share prices are expected to vary each month. As we step into January, prices are projected to range from ₹3,020.92 to ₹3,927.19. In February, they are anticipated to rise to between ₹3,098.38 and ₹4,027.89. March’s prices are forecasted to be between ₹3,219.21 and ₹4,184.98. April will likely see a range from ₹3,156.09 to ₹4,102.92. In May, prices might range from ₹3,064.17 to ₹3,983.42. By June, Medanta’s shares are expected to fluctuate between ₹3,202.05 and ₹4,162.67, followed by July with a range of ₹3,139.27 to ₹4,081.05. In August, the prices are anticipated to be between ₹3,236.36 and ₹4,207.27, while September may see a range from ₹3,349.63 to ₹4,354.52. October’s forecasted prices are between ₹3,436.72 and ₹4,467.74. In November, the range is projected to be from ₹3,522.64 to ₹4,579.43. Finally, as we step into December, Medanta’s share prices are expected to range from ₹3,610.71 to ₹4,693.92.
Financial Condition of Global Health Ltd: Last 5 Years
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
| Sales + | 1,500 | 1,447 | 2,167 | 2,694 | 3,275 |
| Expenses + | 1,309 | 1,250 | 1,709 | 2,073 | 2,476 |
| Operating Profit | 192 | 197 | 458 | 621 | 799 |
| OPM % | 13% | 14% | 21% | 23% | 24% |
| Other Income + | 44 | 31 | 39 | 64 | 75 |
| Interest | 57 | 73 | 86 | 86 | 74 |
| Depreciation | 115 | 123 | 130 | 150 | 173 |
| Profit before tax | 64 | 32 | 281 | 449 | 627 |
| Tax % | 43% | 11% | 30% | 27% | 24% |
| Net Profit + | 36 | 29 | 196 | 326 | 478 |
| EPS in Rs | 7.36 | 5.81 | 7.75 | 12.16 | 17.81 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Medanta has demonstrated a consistent upward trend in its financial performance over the past five years, reflecting its strong growth trajectory and strategic management. The company’s sales have surged from ₹1,500 crore in March 2020 to an impressive ₹3,275 crore in March 2024. This significant increase in revenue highlights Medanta’s expanding market presence and successful business operations.
Despite the rise in expenses from ₹1,309 crore to ₹2,476 crore during the same period, Medanta has effectively managed its costs to ensure profitability. The operating profit saw a substantial improvement, growing from ₹192 crore in March 2020 to ₹799 crore in March 2024. Correspondingly, the operating profit margin (OPM) increased from 13% to a robust 24%, indicating enhanced operational efficiency and profitability.
Additionally, Medanta’s other income has shown a steady increase, rising from ₹44 crore to ₹75 crore. This suggests that the company has diversified its revenue streams and is effectively leveraging additional sources of income. Interest expenses have remained relatively stable, which indicates prudent financial management and controlled borrowing costs.
Depreciation costs, on the other hand, grew from ₹115 crore to ₹173 crore, likely due to investments in infrastructure and technology upgrades. Despite this increase, Medanta’s profit before tax (PBT) experienced a remarkable surge, climbing from ₹64 crore to ₹627 crore. This growth in PBT underscores the company’s ability to generate substantial profits from its core operations.
The effective tax rate for Medanta decreased from 43% in March 2020 to 24% in March 2024, reflecting efficient tax planning and favorable fiscal policies. As a result, the net profit rose dramatically from ₹36 crore to ₹478 crore over the five-year period. This impressive increase in net profit indicates strong financial health and robust earnings growth.
Moreover, earnings per share (EPS) improved significantly, rising from ₹7.36 to ₹17.81, highlighting the company’s enhanced profitability and value generation for shareholders. Notably, Medanta has maintained a 0% dividend payout throughout these years, likely reinvesting its earnings into further growth and expansion initiatives.
Overall, Medanta’s financial performance over the past five years showcases its strong growth, effective cost management, and strategic reinvestment, positioning the company for continued success in the healthcare sector.
FAQs
What is Global Health Ltd current market capitalization?
Global Health Ltd current market capitalization stands at ₹36,016 crore.
What is Global Health Ltd current share price?
As of May 21st, 2024, Global Health Ltd current share price is ₹1,341.
What is Global Health Ltd share price target for 2025?
Global Health Ltd share price target for 2025 ranges from a minimum of ₹1,192.07 to a maximum of ₹1,820.36.
What is Global Health Ltd share price target for 2030?
The projected share price target for Global Health Ltd in 2030 is expected to range between ₹3,020.92 and ₹4,693.92.
What is Global Health Ltd current Price-to-Earnings (P/E) ratio?
Global Health Ltd current Price-to-Earnings (P/E) ratio stands at 75.3.
Also Read
- Delhivery Share Price Target 2024, 2025 to 2030
- NHPC Ltd Share Price Target 2024, 2025 to 2030
- ZYDUS LIFESCIENCES SHARE PRICE TARGET 2024, 2025 TO 2030
Conclusion:
In conclusion, Global Health Ltd, operating under the brand name Medanta, has demonstrated robust financial performance in recent years, highlighted by strong Q4 results. The company achieved a 25% year-on-year increase in net profit and a 14% rise in revenue from operations in Q4 FY24, showcasing effective management and strategic execution. Medanta’s consistent growth in sales, operating profit, and net profit, along with a healthy operating profit margin and efficient cost management, underscores its resilience and operational excellence. The company’s commitment to reinvesting profits for future growth opportunities, evidenced by its decision to maintain a 0% dividend payout, further supports its long-term vision. With a significant presence in the Indian healthcare sector and a promising outlook, Medanta is well-positioned to continue its upward trajectory, delivering value to stakeholders and positively contributing to the healthcare landscape in India.
Having said that, we are not a financial advisor. Please consult a SEBI-registered financial advisor before trading Global Health Ltd. This post on Global Health Ltd share price target from 2024 to 2030 is for educational purposes only.
Leave a Reply